Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update
09. Mai 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 09, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Hold First Quarter 2018 Financial Results and Corporate Update Conference Call on May 9, 2018
26. April 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, April 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018
19. März 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 19, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
15. März 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
13. März 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of Patients No Anti-Drug Antibodies Detected CARMIEL, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- Protalix...
Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update
06. März 2018 07:30 ET
|
Protalix BioTherapeutics, Inc.
Enrollment in all Fabry Trials is ongoing in over Forty Active Sites Current Cash is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020 ...
Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018
26. Februar 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
15. Februar 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the final dosing of the last patient in the Company’s phase II...
Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
31. Januar 2018 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) --
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
29. Januar 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 14th Annual...